19 May 2013
Keywords: genta, antisense, cancer, phase, ii, started, trial
Article | 28 January 1999
Genta has started a trial in the UK of G3139, its bcl-2 gene-targetingantisense drug for the treatment of non-Hodgkin's lymphoma. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 March 1999
17 May 2013
© 2013 thepharmaletter.com